Tag Archives: biomelbourne network

BioBreakfast – Innovation Challenges in Healthcare – 19 Feb 2019

BioMelbourne Network BioBreakfast logo

BioBreakfast:  Innovation Challenges in Healthcare – Tuesday 19th February

BioMelbourne Network BioBreakfast logo
Shaping the Future of Health
BioBreakfast Series
Tuesday, 19 February 2019
Innovation Challenges in Healthcare

Guest speakers: Sue Shilbury, Chief Executive Officer, Austin Health
Craig Bosworth, Group Director, Strategy & Marketing, Cabrini Health

Announcing the BioMelbourne Network 2019 “Shaping the Future of Health” BioBreakfast series, sponsored by the Victorian State Government (DJPR), to lead the conversation in aligning industry growth and economic development with future healthcare needs.

This series of quarterly events brings together players across the health value chain, from industry, research, health, finance and government to explore ways in which Victoria can foster an innovation driven, technology enabled healthcare system. 
Join us for our first event in February 2019 “Innovation Challenges in Healthcare” with hospital executives Sue Shilbury, Chief Executive Officer, Austin Health and Craig Bosworth, Group Director, Strategy & Marketing, Cabrini Health. Our speakers will share their views on innovation challenges, insights into future service delivery aspirations, market players and sector trends, and explore ways to bring about change in the healthcare system to address unmet patient needs.  

When Tuesday, 19 February 2019
Time  7:20 am – Registration 7:30 am – Networking breakfast  8:00 am – Presentations and discussion  9:00 am – Ends
Where The Cube, ACMI, Federation Square, Melbourne
Cost BioMelbourne Network Members: $65;
Non-members: $130 (prices include GST)

Check if your organisation is a member      

Sue Shilbury, Chief Executive Officer, Austin Health
Sue Shilbury joined Austin Health as CEO in early 2017, following a three-decade career in the New South Wales (NSW) public health sector. Sue was General Manager of North Shore Ryde Health Service where she oversaw the delivery of NSW Health’s largest capital works program, the $1.3 billion redevelopment of Royal North Shore Hospital. Sue has also held roles as General Manager of the Central Hospital Network (South Eastern Sydney and Illawarra Health District), Director of the Division of Critical Care and Surgery at St George Hospital, and Director of Clinical Services at the Royal Hospital for Women.      

Craig Bosworth, Group Director, Strategy & Marketing, Cabrini Health
Craig joined Cabrini in July 2018. His experience covers a range of sectors across primary and tertiary healthcare, compensable and private health insurance, aged care and the National Disability Insurance Scheme. Having graduated as a physiotherapist, he became a Director of Olympic Park Sport Medicine Centre before working for a number of organisations including TAC, Worksafe, Medibank Private, Healthways Australia and Healthdirect Australia. He was Chief of Staff to the Federal Minister for Health, Aged Care and Sport from 2015 to 2016. Craig holds an MBA from Melbourne Business School, and has studied at Wharton (finance), Stanford (strategy) and Monash (health economics) universities. He is a Graduate of the Australian Institute of Company Directors. He is a past Director of Comcare, Multicultural Arts Victoria and the NSW Ministerial Advisory Board for Preventative Health.

This article appears courtesy of our proud precinct partner, BioMelbourne Network

Hot or Not: Trends for 2019 – 7 Feb 2019

logo for BioBriefing
logo for BioBriefing

What lies ahead for Melbourne’s biotechnology, medical technology and pharmaceutical industry in 2019? BioMelbourne Network’s annual “Hot or Not” discussion explores the global trends for the coming year with 4 speakers each presenting a short “snap shot” of what is HOT and what is NOT going into 2019 in their area of interest and expertise.

Topics for discussion include:

AI & IP – Raffaele Calabrese, Patent Attorney, Phillips Ormonde Fitzpatrick 
Exosomes – Dr Ian Dixon, CEO & Founder, Exopharm Ltd (ASX-EX1) 
Consumer Health – Swisse Wellness 
JP Morgan conference insight – Market/Sector Trends – Sam Cobb, Managing Director & Chief Executive Officer, Adalta

Thursday – 7 February 2019

3:45pm Registrations
4:00–5:25pm Presentations and Q&A
Networking until 6:30pm

Phillips Ormonde Fitzpatrick, Level 16, 333 Collins Street, Melbourne

BioMelbourne Network Members: $65
Non-members: $130
(prices include GST)
Check if your organisation is a member

Raffaele Calabrese, Patent Attorney, Phillips Ormonde Fitzpatrick

Raffaele has a background in electrical and electronic engineering, and a master’s degree in engineering specialising in information technology and telecommunications. He has had over ten years of professional experience in protecting inventions relating to ICT, software and engineering.

Raffaele began his intellectual property (IP) career in 2005 as a Technical Assistant with an IP firm in Adelaide. In 2007, he moved to Melbourne and joined a large IP firm, where he specialised in drafting and prosecuting patent applications in Australia and overseas. During this time, he also gained experience in assisting Australian and international clients with obtaining trade mark and design protection.

Raffaele’s background provides him with an in depth understanding of a wide range of electronic and mechanical inventions. He also has experience in protecting computer implemented inventions, including Fin Tech inventions, mining, energy and medical technologies.

Dr Ian Dixon, CEO & Founder, Exopharm Ltd

Dr Dixon brings to the Exopharm Board an extensive technical and entrepreneurial background in founding, building and running technology-based companies, in recognising the potential commercial value of early-stage drug development, and in understanding the challenges involved in drug development.

In 2011, Dr Dixon Co-Founded Cynata Inc, a company that is progressing the commercialisation of what has become the Cymerus technology of ASX-listed Cynata Therapeutics Ltd (ASX-CYP). 

Dr Dixon is also a non-executive director of Noxopharm Ltd (ASX-NOX); a founder of Nyrada Inc.; a co-inventor of Nyrada drug NYX-330; founder of Genscreen Pty Ltd (2003-2018) and; former director of Cell Therapies Pty Ltd. Dr Dixon currently also serves as a part-time executive director of Medigard Ltd (ASX:MGZ). 

Dr Dixon is a co-inventor of the LEAP Technology now owned by Exopharm.

Dr Ian Dixon has a PhD in biomedical engineering from Monash University, an MBA from Swinburne University and professional engineering qualifications.

Sam Cobb, Managing Director & Chief Executive Officer, Adalta

Sam is the founding CEO of AdAlta and has over fifteen years’ experience in business development and commercialisation of early stage scientific technologies. 

Prior to AdAlta, Sam was the Business Development Director at the Co-operative Research Centre for Diagnostics. Sam has also worked for the biotech start up companies Sensologix Inc and Nephrogenix Pty Ltd and at the University of Queensland’s technology commercialisation companies, Uniquest Pty Ltd and IMBcom Pty Ltd. 

Sam has a Bachelor of Science, a Masters of Intellectual Property Law and has completed the Australian Institute of Company Directors course.